PrimeGene
Latest round
- Series B
Last raised
- Jan 2025
Total raised
- $55M
Investors
- 8
About PrimeGene
Founded in 2016 and based in Beijing, China, PrimeGene operates as a biopharmeceutical company that focuses on the innovative drug developer that specializes in the research and development of immuno-inflammatory disease drugs and related products. It acquired 7 clinical approvals in 2023. The company acquired certifications such as quality management system and Zhongguancun High-tech Enterprise, etc. Yunlong Du, the CEO of the company, graduated from Albany Medical College in the United States, and worked in Pfizer, GSK and other pharmaceutical companies for more than 20 years. In 2022, the company was listed on the New Third Board. PrimeGene mainly engages in the research and development and industrialization of innovative immune-inflammatory drugs. Its product pipelines can be categorized into 4 series, which are dermatology, ophthalmology, rhinology and respiratory system. The dermatology products include PG- 019, PG-033, etc. The company adopts technologies such as computer-aided drug design, first-to-compound optimization, target analysis and precision screening. Products can be used in the treatment of atopic dermatitis, chronic itchy rash, glaucoma and other diseases. The company generates revenue by selling immune-inflammatory drugs. The company will use the funds for researching Atopic Dematitis AD, claiming NDA, and expanding application and innovation of PG-011.
Who invested in PrimeGene
8 investors across 2 rounds
See all investors in PrimeGene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about PrimeGene
Who invested in PrimeGene?
PrimeGene has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has PrimeGene raised?
PrimeGene has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did PrimeGene last raise money?
PrimeGene's most recent round on record is a Series B, in Jan 2025.
What does PrimeGene do?
Founded in 2016 and based in Beijing, China, PrimeGene operates as a biopharmeceutical company that focuses on the innovative drug developer that specializes in the research and development of immuno-inflammatory disease drugs and related products.
Where is PrimeGene headquartered?
PrimeGene is headquartered in Shanghai, China.
Which VCs invest in companies like PrimeGene?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at PrimeGene's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like PrimeGene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.